UK-based healthcare group, Alliance, has announced that it has appointed New Delhi-based Alniche as its exclusive marketing partner in India to market and distribute the Nizral and Nizoral range of formulations. According to reports, the transfer of the business was successfully concluded during September.
Rajiv Ghildiyal, Alliance’s regional business director – Central Asia, Middle-East & Pacific, commented, “With the acquisition of a great brand comes great responsibility, as we look to take over and maintain the long-standing quality, heritage and brand awareness built by our J&J colleagues over the past decades. Together with the marketing and distribution excellence of our local partner Alniche Life Sciences, we aim to consolidate and expand this awareness and reach beyond Metro’s and Class A towns so that more of the Indian population can benefit from this time-tested remedy for scalp and related skin conditions.”
Girish Arora, founder and managing director of Alniche Lifesciences, expressed, “Nizral is a welcome addition in our product portfolio. With Nizral’s excellent brand equity and seal of quality Alniche is confident to build this brand to attain leader position in Antidandruff market.”
In 2018, Alliance further strengthened its consumer healthcare portfolio with the acquisition of medicated antidandruff shampoo and lotion (lotion currently only available in Japan), Nizoral, from Janssen Pharmaceutical (a member of the Johnson & Johnson group) for the APAC (Asia Pacific) region. This acquisition significantly increased the Alliance’s presence in the 15 countries where Nizoral is currently registered. In India, Nizoral is registered as Nizral 2% and Nizoral 1%, both part of this acquisition. Janssen discovered Nizoral’s API, ketoconazole (antifungal), in 1976. More than 50 clinical studies are carried out, it is one of the most widely prescribed antifungal medicine in the world, treating seborrheic capitis (dandruff), seborrheic dermatitis, pityriasis versicolor.
The company said Nizral 2% (exclusive to ethical channels) and Nizoral 1% (over-the-counter availability), with its strong clinical heritage, well-established safety profile, and long history of use, continues to be one of the top Medicated Anti-dandruff brands in India. Nizral continues to be manufactured within the same state-of-the-art manufacturing facilities of Encube Ethicals who continue to be the manufacturer for this product.
From its origins in the UK more than 20 years ago, Alliance Pharma has grown to become a significant international healthcare group, marketing more than 90 consumer healthcare brands and prescription medicines in over 100 countries worldwide and employing over 200 people.
Recent years have seen a broadening in the scope of Alliance’s product portfolio. In addition to the established niche prescription products that formed the Group’s activities’ original focus, the Group’s portfolio now includes a significant number of consumer products, covering a wide range of therapy areas. In addition to its UK presence, the Group now has eight other offices across Europe, the Far East, and the US. This geographic presence is enhanced by a broad network of international distributors, covering more than 100 countries worldwide. To demonstrate its commitment to the Indian market, Alliance CHC (India) was incorporated during August 2020, with its office located in Mumbai’s bustling city.
New Delhi-based Alniche Life Sciences serves patients and the medical fraternity by offering specialized, high-quality, effective, affordable medicines and wellness products. Their 700 sales team members cover 70,000 doctors and 30,000 hospitals with a strong portfolio of domestic and licensed brands from global partners in nephrology, critical care, gastroenterology, dermatology, neurology, and advanced wound care.
Alniche has partnered with global pharma organizations to bring novel global brands in India, including Alliance, J W Life Science, Adhezion Biomedical, FzioMed, PT Dermozone Pratama, Biovite, and Dongkook.